Mode
Text Size
Log in / Sign up

MBCT plus escitalopram improves cognitive function and depression severity in older adults with TRDMindfulness Therapy Combined With Medication Helps Seniors with Depression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider adding MBCT to escitalopram for older adults with TRD and cognitive impairment to improve outcomes.

This randomized controlled trial enrolled 230 older adults diagnosed with treatment-resistant depression (TRD) and concurrent cognitive impairment. The study compared a combination of mindfulness-based cognitive therapy (MBCT) plus escitalopram hydrobromide against a control group receiving escitalopram alone over a 12-week follow-up period.

Primary outcomes included cognitive function, depression severity, and quality of life. Results showed that the experimental group achieved significant improvements in MoCA scores at both 6 and 12 weeks (p < 0.05). Quality of life as measured by GQOLI-74 scores also showed significant improvement compared to the control group at 6 and 12 weeks (p < 0.05). Additionally, HAM-D scores were significantly reduced in the experimental group (p < 0.05).

Secondary outcomes indicated higher rates of significant and effective treatment outcomes in the MBCT plus escitalopram group compared to the control group (p < 0.05). No specific data regarding adverse events, serious adverse events, or discontinuation rates were reported. A notable limitation is that the trial was retrospectively registered.

Clinicians may consider incorporating mindfulness-based interventions alongside pharmacological treatments for older adults with TRD. However, the retrospective registration of the study suggests some caution in interpreting the strength of the evidence.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in management strategies for treatment-resistant depression in elderly populations with cognitive impairment. While previous coverage highlighted risks associated with SSRI combinations in Parkinson's patients, this trial focuses on the additive benefit of mindfulness-based cognitive therapy when combined with an SSRI (escitalopram) for TRD.

Researchers conducted a randomized controlled trial involving 230 older adults who had treatment-resistant depression and some cognitive impairment. The study compared two different approaches: one group received only the medication escitalopram, while the other group received both escitalopram and mindfulness-based cognitive therapy (MBCT).

The results showed that patients who received both the medication and mindfulness training saw significant improvements in their mood and quality of life after 6 and 12 weeks. These participants also showed better scores on tests measuring cognitive function compared to those who took only the medication. Additionally, the group receiving combined treatment had higher rates of effective outcomes.

While these results are promising for older adults with complex depression, it is important to note that this was a retrospectively registered trial. The study did not report any specific side effects or reasons for patients stopping treatment. Because individual needs vary greatly, talk to your doctor about whether adding mindfulness techniques to your current plan is right for you.

What this means for you:
Combining mindfulness therapy with medication may improve mood and memory in older adults with severe depression.

Common questions

Can mindfulness help with memory issues in older adults with depression?

The study found that older adults who received both escitalopram and mindfulness-based cognitive therapy showed significant improvements in cognitive function scores at 6 and 12 weeks. These results were compared to a group taking only the medication. You should discuss these findings with your doctor to see if this approach fits your specific needs.

How does combining mindfulness with medication compare to medicine alone?

Patients who received both mindfulness-based cognitive therapy and escitalopram showed higher rates of effective treatment outcomes. They also experienced significant reductions in depression severity compared to the group that took only the medication. This suggests a combined approach may be more effective for some older adults.

Is it safe to add mindfulness-based therapy to my current treatment?

The study did not report any specific side effects or safety concerns regarding the combination of mindfulness and medication. However, because every patient is different, you must consult your healthcare provider before making any changes to your current treatment plan for depression.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up1.4 mo
PublishedAug 2026
View Original Abstract ↓
OBJECTIVES: This study investigates the adjunctive effects of mindfulness-based cognitive therapy (MBCT) combined with escitalopram hydrobromide on cognitive function and emotional well-being in older adults with treatment-resistant depression (TRD). We hypothesized that this combined approach would lead to greater enhancements in cognitive abilities and overall well-being compared to escitalopram hydrobromide alone in this vulnerable population. METHODS: A total of 230 older adults with TRD and cognitive impairment were randomly assigned into two groups: an experimental group receiving MBCT plus escitalopram (n = 115) and a control group receiving escitalopram alone (n = 115). Cognitive function, depression severity, and quality of life were assessed at baseline, 6 weeks, and 12 weeks using the Montreal Cognitive Assessment (MoCA), Hamilton Depression Rating Scale (HAM-D), and General Quality of Life Index-74 (GQOLI-74). RESULTS: The experimental group demonstrated significant improvements in cognitive function (MoCA scores) and quality of life (GQOLI-74 scores) compared to the control group at both 6 and 12 weeks (p < 0.05). Additionally, depression severity (HAM-D scores) was significantly reduced in the experimental group (p < 0.05). The combined therapy also resulted in higher rates of significant and effective treatment outcomes, with fewer cases of average or ineffective responses (p < 0.05). CONCLUSIONS: The integration of MBCT with escitalopram hydrobromide significantly enhances cognitive function, reduces depressive symptoms, and improves quality of life in older adults with TRD. CLINICAL IMPLICATIONS: Clinicians should consider incorporating mindfulness-based interventions alongside pharmacological treatments for older adults with TRD. TRIAL REGISTRATION: The trial was retrospectively registered with ClinicalTrials. gov (Identifier: NCT07077291).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.